المؤلفون: Yuji Matsumoto, Yuichiro Ohe, Hidehito Horinouchi, Ryota Shibaki, Shuji Murakami, Noboru Yamamoto, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, Tatsuya Yoshida

المصدر: Thoracic Cancer

مصطلحات موضوعية: non‐small cell lung cancer, Adult, Male, 0301 basic medicine, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Lung Neoplasms, Multivariate analysis, soluble PD‐L1, Pembrolizumab, Antibodies, Monoclonal, Humanized, Gastroenterology, Programmed cell death ligand 1, 03 medical and health sciences, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Internal medicine, mental disorders, medicine, Humans, Anti‐PD‐1 antibody, In patient, Lung cancer, Aged, Aged, 80 and over, biology, business.industry, Hazard ratio, Original Articles, General Medicine, PD‐L1 TPS, Middle Aged, Prognosis, medicine.disease, Survival Analysis, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, biology.protein, Original Article, Female, Nivolumab, Antibody, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19fced2ae8c7ae9ecc4e68e52a492d5dTest
https://doi.org/10.1111/1759-7714.13721Test

المؤلفون: Kai Wang, Xiangdong Zhou, Qi Wang, Xiaoxia Cui, Xiaoyu Zhang, Chunxue Bai, Li Zhang, Jian Zhang, Jianping Zhao, Peng Song, Xiaoju Zhang, Faguang Jin, Yao Yu, Li Bai, Xiaoli Zhu, Yanbin Zhou, Chengzhi Zhou

المصدر: Thoracic Cancer

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Lung Neoplasms, Adolescent, medicine.medical_treatment, Programmed Cell Death 1 Receptor, Pembrolizumab, NSCLC, Multi‐omics, B7-H1 Antigen, Young Adult, Study Protocol, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, PD‐1/PD‐L1 inhibitor, Carcinoma, Non-Small-Cell Lung, PD-L1, Internal medicine, Biomarkers, Tumor, medicine, Humans, Molecular Targeted Therapy, predictive biomarker, Lung cancer, Aged, Response rate (survey), biology, business.industry, General Medicine, Immunotherapy, Middle Aged, medicine.disease, Clinical trial, Treatment Outcome, 030104 developmental biology, 030220 oncology & carcinogenesis, biology.protein, Immunohistochemistry, Female, Nivolumab, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adb9f8018da18f4739ee639337e1c7efTest
https://doi.org/10.1111/1759-7714.13078Test

المؤلفون: Kazushige Wakuda, Satoshi Ikeda, Masafumi Sata, Ryota Ushio, Kentaro Ito, Takashi Sato, Shigeru Tanzawa, Naoki Furuya, Makoto Nishino

المصدر: Thoracic Cancer
Thoracic Cancer, Vol 12, Iss 5, Pp 613-618 (2021)

مصطلحات موضوعية: 0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, Adult, Male, atezolizumab, non‐small cell lung cancer, medicine.medical_specialty, Lung Neoplasms, Pembrolizumab, Antibodies, Monoclonal, Humanized, lcsh:RC254-282, Cohort Studies, 03 medical and health sciences, anti‐PD‐L1, 0302 clinical medicine, Atezolizumab, Internal medicine, Carcinoma, Non-Small-Cell Lung, medicine, Humans, Lung cancer, Immune Checkpoint Inhibitors, Aged, Retrospective Studies, Aged, 80 and over, Performance status, business.industry, Anti pd 1, General Medicine, Original Articles, Middle Aged, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Confidence interval, 030104 developmental biology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Retreatment, Female, Original Article, Nivolumab, business, Cohort study

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12194075aa42c60389387090977b3ce3Test
https://pubmed.ncbi.nlm.nih.gov/33448648Test